Page 8 - Polypeptide Group News Today

Generic Segment to Grow at Faster Pace during Forecast Period Peptide Therapeutics Market is expected to reach US$ 50,003.15 million by 2027 from US$ 24,878.55 million in 2019; it is estimated to grow at a CAGR of 9.2% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The growth of the peptide therapeutics market is mainly attributed to the growing investments on peptide therapeutics and increasing prevalence of me...

PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange EQS Group-News: PolyPeptide Group / Key word(s): IPO 12.04.2021 / 07:00 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON T...

3 Min Read ZURICH (Reuters) - PolyPeptide Group, controlled by a foundation of Swedish billionaire adventurer Frederik Paulsen Jr., said Monday it plans to list a 40% stake on the Swiss stock exchange to finance the contract drug maker’s growth. The company, which makes ingredients for U.S.-based Novavax Inc’s, COVID-19 vaccine candidate, plans to list in the second quarter. It plans to place existing shares and a primary offering, with some proceeds to go for potential acquisitions. PolyPe...

Share this article Share this article ResearchAndMarkets.coms offering. This report provides insights into the potential application of peptide therapeutics and their mode of action in the management of different cancers. In addition to this, the report also provide data on the pricing, sales and dosage of the currently available peptide based therapeutics and the robust clinical pipeline which are expected to enter the market in next coming years. Moreover, the various key players which are in...

Mar 3, 2021 9:45am COVID-19 vaccine shipments are now underway. Here are the supply chains tasked with producing billions of doses. (nevodka/iStock/Getty Images Plus/Getty Images) As COVID-19 gained steam worldwide last spring, little was known about the disease and the havoc it would wreak on the world. A year later, vaccines offer hope in the fight against the virus, but it will be a monumental task to produce them and deliver them around the planet. That these vaccines were invented, put th...

Published: Feb 19, 2021 By Alex Keown PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she crea...

Read more about PolyPeptide Group names new CEO before likely Swiss IPO during 2021 on Business Standard. Raymond De Vre, a Belgian who previously worked at Indian contract manufacturer Dr. Reddys Laboratories as global head of biologics, will join PolyPeptide Group as CEO-elect in April

Advanced Peptide Synthesis Program Uses Predictive Modeling and Simulation Tools to Shorten Peptide Process Development The field of Solid Phase Peptide Synthesis (SPPS) has boomed over the last few decades. But many companies are still relying on procedures used in the laboratory to achieve large-scale production. This has proven to be inefficient and not cost-effective. Not surprisingly, the overall quest to produce high-quality peptides at lower costs while meeting customers’ expectations ...